Drugs / DXC006
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06224855 | Jan 2024 → Jun 2027 expected | cancer, hematopoietic and lymphoid cell neoplasm | Hangzhou DAC Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07559929 | Aug 2026 → Jun 2028 expected | small cell lung carcinoma | Hangzhou DAC Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DXC006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07559929 ↗ |
| Route | Intravenous | “DXC006 is administered intravenously” NCT06224855 ↗ |